Eric L. Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eric L. Allen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alena Zalutskaya
Blueprint Medicines Corporation, Cambridge, Massachusetts
7 shared publications - Christine Lihou
Tyra Biosciences, Carlsbad, California
7 shared publications - Cédric Pobel
Département d'Innovation Thérapeutique et Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Inserm U981, Gustave Roussy, Villejuif, France; Université Paris-Saclay, Gustave Roussy, Villejuif, France; Département de Médecine Oncologique, Gustave Roussy, Villejuif, France
7 shared publications - Erik Goluboff
Tyra Biosciences, Carlsbad, California
7 shared publications - Jacqueline H. Starrett
Tyra Biosciences, Carlsbad, California
7 shared publications - Jesús Fuentes Antrás
NEXT Oncology, Hospital Universitario Quirónsalud Madrid, Madrid, Spain
7 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Supplementary Data file describes the structure and synthesis method for dabogratinib.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Supplementary Data file describes the structure and synthesis method for dabogratinib.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::TACC3 fusion. CT images of a target lesion in the liver (A) and nontarget lesions in the liver (B) are shown at baseline and at 15.4 weeks as a confirmatory PR.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::TACC3 fusion. CT images of a target lesion in the liver (A) and nontarget lesions in the liver (B) are shown at baseline and at 15.4 weeks as a confirmatory PR.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3S249C mutation. CT images of a target lesion in the lung are shown at baseline and at 15.7 weeks as a confirmatory PR.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3S249C mutation. CT images of a target lesion in the lung are shown at baseline and at 15.7 weeks as a confirmatory PR.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::JAKMIP1 fusion. CT images of target lesions in the lung are shown at baseline, first partial response at 8 weeks, and at 15.7 weeks as a confirmatory PR.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::JAKMIP1 fusion. CT images of target lesions in the lung are shown at baseline, first partial response at 8 weeks, and at 15.7 weeks as a confirmatory PR.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates in vitro and in vivo efficacy in FGFR3-driven bladder cancer models. A, Assessment of downstream signaling after treatment for 2 hours with dabogratinib at the indicated dose or vehicle control in the indicated FGFR3-driven bladder cancer cell lines. One representative biological replicate is shown on the left and quantification of the ratio of pERK to tERK of n = 3 biological replicates is shown on the right. B and C, Antitumor activity in the FGFR3S249C-activating mutant UM-UC-14 bladder cancer xenograft model in nu/nu mice of various dosages of dabogratinib: (B) 3, 6, and 9 mg/kg twice daily and (C) 6, 12, and 18 mg/kg once daily and erdafitinib (12.5 mg/kg twice daily) shown in both B and C. D and E, Body weight averages for the dosage groups depicted in B and C, respectively. All dosages were by oral administration. Data in B–E were derived from the same study but split into separate graphs to enable visualization of each group. Data from vehicle- and erdafitinib-treated groups were repeated in B and C, as well as in D and E. Data points represent mean tumor volume (n = 6 per group, except 6 mg/kg twice daily dabogratinib dosing group in which one animal was found dead at day 7 of treatment, with n = 5) and error bars represent SEM.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates in vitro and in vivo efficacy in FGFR3-driven bladder cancer models. A, Assessment of downstream signaling after treatment for 2 hours with dabogratinib at the indicated dose or vehicle control in the indicated FGFR3-driven bladder cancer cell lines. One representative biological replicate is shown on the left and quantification of the ratio of pERK to tERK of n = 3 biological replicates is shown on the right. B and C, Antitumor activity in the FGFR3S249C-activating mutant UM-UC-14 bladder cancer xenograft model in nu/nu mice of various dosages of dabogratinib: (B) 3, 6, and 9 mg/kg twice daily and (C) 6, 12, and 18 mg/kg once daily and erdafitinib (12.5 mg/kg twice daily) shown in both B and C. D and E, Body weight averages for the dosage groups depicted in B and C, respectively. All dosages were by oral administration. Data in B–E were derived from the same study but split into separate graphs to enable visualization of each group. Data from vehicle- and erdafitinib-treated groups were repeated in B and C, as well as in D and E. Data points represent mean tumor volume (n = 6 per group, except 6 mg/kg twice daily dabogratinib dosing group in which one animal was found dead at day 7 of treatment, with n = 5) and error bars represent SEM.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- Open Access
- 13 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (3) , 408-415
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- 13 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (3) , 408-415
Open AccessDabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.